The objective of this study was to identify proteins that are differentially expressed in the cystic wall tissues of ovarian endometriotic cysts, simple ovarian cysts, and in normal ovarian tissues. Specimens of ovarian endometriotic cyst wall tissue, simple ovarian cyst wall tissue, and normal ovarian tissue (six specimens per group) were collected from patients who received gynecologic surgery, respectively. Differentially expressed proteins related to the ovarian endometriotic cysts were screened by use of isobaric tags for relative and absolute quantitation (iTRAQ) combined with functional annotation and bioinformatics analyses. All differentially expressed proteins related to cysts were validated using immunohistochemistry methods in recurrent and non-recurrent ovarian endometriotic cyst. A total of 359 proteins were identified as up-regulated in ovarian endometriotic cyst groups when compared with both the normal ovary and simple ovarian cyst groups. The levels of 27 proteins were >two-fold higher in the ovarian endometriotic cyst group than that in the other two groups. Of note, the five most significantly upregulated proteins were Charcot-Leyden Crystal Galectin (CLC), Defensin, alpha 1 (DEFA1), S100 calcium-binding protein A9 (S100A9), S100 calcium-binding protein A8 (S100A8), and Ferritin Light Chain (FTL). Immunohistochemistry results showed that the changes of S100A9 and S100A8 were consistent with the results shown by iTRAQ. However, no similarity of CLC, DEFA1, and FTL proteins was found between iTRAQ and immunohistochemistry. The ratio of patients with abnormally high S100A9 and S100A8 expression in the recurrent ovarian endometriotic cyst group was significantly higher than that in the non-recurrent group (P < 0.05). Our data identify differentially expressed proteins S100A9 and S100A8, and suggest they may serve as novel molecular markers to predict postoperative recurrence of an ovarian endometriotic cysts.Abbreviations: iTRAQ: isobaric tags for relative and absolute quantitation; HPRD: Human Protein Reference Database; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; EM: Endometriosis; COX-2: cyclooxyenase-2; NF-kB: nuclear factor kappa-B; PR-B: progesterone receptor type B.

中文翻译：

---

鉴定与子宫内膜异位囊肿复发相关的差异表达蛋白。

本研究的目的是鉴定在子宫内膜异位囊肿，单纯卵巢囊肿和正常卵巢组织的囊壁组织中差异表达的蛋白质。分别从接受妇科手术的患者中收集卵巢子宫内膜异位囊肿壁组织，单纯卵巢囊肿壁组织和正常卵巢组织（每组六个标本）的标本。通过使用等压标签对相对和绝对定量（iTRAQ）结合功能注释和生物信息学分析，筛选与卵巢子宫内膜异位囊肿相关的差异表达蛋白。使用免疫组织化学方法验证了复发性和非复发性卵巢子宫内膜异位囊肿中与囊肿相关的所有差异表达蛋白。与正常卵巢和单纯卵巢囊肿组相比，在卵巢子宫内膜异位囊肿组中总共鉴定出359种蛋白质。卵巢子宫内膜异位囊肿组中27种蛋白质的水平比其他两组高出两倍以上。值得注意的是，五个最显着上调的蛋白是Charcot-Leyden Crystal Galectin（CLC），Defensin，alpha 1（DEFA1），S100钙结合蛋白A9（S100A9），S100钙结合蛋白A8（S1​​00A8）和Ferritin Light链（FTL）。免疫组织化学结果表明，S100A9和S100A8的变化与iTRAQ显示的结果一致。但是，在iTRAQ和免疫组织化学之间没有发现CLC，DEFA1和FTL蛋白的相似性。复发性卵巢子宫内膜异位囊肿组中S100A9和S100A8表达异常高的患者比例显着高于非复发组（P <0.05）。我们的数据鉴定了差异表达的蛋白S100A9和S100A8，并暗示它们可能作为预测卵巢子宫内膜异位囊肿术后复发的新型分子标记。HPRD：人类蛋白质参考数据库；GO：基因本体论；KEGG：《京都基因与基因组百科全书》；EM：子宫内膜异位；COX-2：环氧合酶-2；NF-kB：核因子κB；PR-B：孕激素受体B型。我们的数据鉴定了差异表达的蛋白S100A9和S100A8，并暗示它们可能作为预测卵巢子宫内膜异位囊肿术后复发的新型分子标记。HPRD：人类蛋白质参考数据库；GO：基因本体论；KEGG：《京都基因与基因组百科全书》；EM：子宫内膜异位；COX-2：环氧合酶-2；NF-kB：核因子κB；PR-B：孕激素受体B型。我们的数据鉴定了差异表达的蛋白S100A9和S100A8，并暗示它们可能作为预测卵巢子宫内膜异位囊肿术后复发的新型分子标记。HPRD：人类蛋白质参考数据库；GO：基因本体论；KEGG：《京都基因与基因组百科全书》；EM：子宫内膜异位；COX-2：环氧合酶-2；NF-kB：核因子κB；PR-B：孕激素受体B型。核因子κB; PR-B：孕激素受体B型。核因子κB; PR-B：孕激素受体B型。